In the morning of January 13, 2022, Chen Kui, deputy Director of Zhejiang Provincial Drug Administration, and Zhu Zhiquan, president of Zhejiang Pharmaceutical Association, led a team to investigate and investigate zhejiang Province pharmaceutical MAH transformation platform, and had in-depth discussions and communication with platform and representative member enterprise Heze Pharmaceutical on MAH practical experience and existing problems. Lu Jianjun, deputy secretary of party Working Committee and director of management office of Hangzhou Pharmaceutical Port, attended the meeting.

The MAH system has been piloting since 2015 and was officially implemented on December 1, 2019. Chen Kui, deputy director of Zhejiang Provincial Food and Drug Administration, mentioned that the MAH system is still a novelty for regulators and is still in the stage of "encouraging development and supporting policies" in China. However, MAH has brought vitality and reform to the whole industry after two years of implementation. Up to now, Zhejiang Province has approved more than 30 B certificates (drug production licenses). Of course, in the process of MAH practice, there are still many links worthy of exploration and research. The policy research of Zhejiang Pharmaceutical MAH Transformation Platform (hereinafter referred to as the platform) takes the lead, and it is of great significance to provide certain data support for regulatory agencies through solid subject research.

At the forum, Zhu Zhiquan, chairman of Zhejiang Pharmaceutical Society, put forward requirements for the platform and expected the platform to play a greater role in serving the government in the future.

The platform now has more than 1300 member enterprises, with the purpose of serving the pharmaceutical industry in the province, facilitating the transformation of pharmaceutical industry marketing license and promoting the development of pharmaceutical economy, is a non-profit comprehensive service platform to provide pharmaceutical license transformation services for pharmaceutical marketing license holders.

In the future, the platform will strengthen research on MAH related topics, provide suggestions and suggestions to the regulatory authorities, and jointly promote the development of MAH system in China.

Wu Yue, Drug production Department of Zhejiang Drug Administration, Li Jinhe, Drug Inspection Center, Yang Subei, secretary general of Zhejiang Pharmaceutical Association, Zhou Jianhui, deputy secretary general attended the meeting.

Reprinted from: Zhejiang Pharmaceutical MAH Transformation Platform public number